An official website of the United States government
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Trial Status: active
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of
HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that
consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a
combination dose expansion. Approximately 80 patients will be enrolled in this study (up
to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients
into the combination dose escalation, and up to 30 patients into the combination dose
expansion). The primary purpose of this study is to determine the maximum tolerated dose
of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable)
or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene
mutation status.
Inclusion Criteria
Inclusion Criteria:
- Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant
clear cell component
- Be age 18 years or older (male or female) at the time of consent
Additional locations may be listed on ClinicalTrials.gov for NCT06234605.
